10月23日 - ** 生物技术公司莫德纳 MRNA.O在试验受挫后停止开发出生缺陷疫苗 (link)，盘前股价下跌3.5%，至25.91美元。
** 实验性巨细胞病毒(CMV) mRNA-1647疫苗在7500名妇女中的有效率为6%至23%，未达到公司在最后阶段试验中设定的目标。
** CMV 如果在怀孕期间由母亲传染给婴儿，会导致出生缺陷；目前还没有获得批准的疫苗可以治愈这种疾病
* MRNA 预计到 2028 年无法实现试验收支平衡的目标
**公司预计试验失败不会影响 2025 年的前景
** 25位分析师中有4位给予 "买入 "评级，16位给予 "持有 "评级，5位给予 "卖出 "或以下评级；PT中值为30.50美元--数据由LSEG编制
** 截至周三收盘，MRNA股价累计下跌35.43%、
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.